Literature DB >> 477020

Catecholamine metabolism in familial amyloid polyneuropathy.

T Suzuki, I Tsuge, S Higa, A Hayashi, Y Yamamura, Y Takaba, A Nakajima.   

Abstract

In order to evaluate the involvement of the peripheral autonomic nervous system in the pathogenesis of type 1 familial amyloid polyneuropathy, the urinary excretion rates of catecholamines and serum dopamine-beta-hydroxylase (DB/) activity were examined in 22 patients at various clinical stages. Changes in both indices were closely linked to the progression of the illness; urinary excretion rates of catecholamines were first decreased in patients suffering from moderate autonomic dysfunction, while serum DBH activity was significantly reduced only in patients with far advanced disease. These findings suggested that patients with advanced disease might be suffering from a chronic deficiency of catecholamines in the peripheral sympathetic nerves. Administration of L-dopa, however, failed to improve the clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477020     DOI: 10.1111/j.1399-0004.1979.tb00860.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?

Authors:  L Bernardi; C Passino; C Porta; E Anesi; G Palladini; G Merlini
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

2.  Plasma catecholamines and postural hypotension in familial amyloidotic polyneuropathy of the Portuguese type.

Authors:  J Ducla-Soares; L Breitenfeld; P Póvoa; M Ferreira; M Carvalho; M Alves; M Bicho; M de L Sales-Luis; C Manso; A da Palma-Carlos
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

3.  The aortic alpha 1-adrenergic receptor in familial amyloidotic polyneuropathy.

Authors:  T Azuma; Y Watanabe; T Suzuki; S Sakoda; S Higa; R Mizuno; S Tsujino; S Kishimoto; H Yoshida
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 4.  Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.

Authors:  T Nakajima
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

5.  Disturbed function of the pineal gland in familial amyloid polyneuropathy.

Authors:  S Higa; T Suzuki; S Sakoda; S Kishimoto; Y Takaba; A Nakajima; S P Markey
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

6.  Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; S Sakoda; M Ueji; A Hayashi; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  DL-threo-DOPS as a precursor of noradrenaline.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

8.  Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; I Tsuge; S Sakoda; A Hayashi; Y Yamamura; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.